Adjuvant CDK4/6 Benefits Diverge in Early Breast Cancer
A 2026 meta-analysis found abemaciclib and ribociclib improved invasive disease-free survival in early HR-positive, HER2-negative breast cancer, unlike palbociclib, supporting drug-specific selection.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.